Elranatamab Combination Therapy
Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma, a Clinical and Correlative Phase 2 Study
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 104 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Pfizer
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2128
- NCT Identifier
- NCT06997081
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.